 | • レポートコード：MRC2109A044 • 出版社/出版日：Transparency Market Research / 2021年7月6日 • レポート形態：英文、PDF、190ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Site Licence | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Enterprisewide | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査レポートは、医薬品中間体の世界市場について調査し、序論、仮定/調査手法、エグゼクティブサマリー、市場概要、主要インサイト、製品別（バルク薬物中間体、カスタム中間体）分析、用途別分析、エンドユーザー別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを掲載しております。 ・序論 ・仮定/調査手法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・医薬品中間体の世界市場規模：製品別（バルク薬物中間体、カスタム中間体） ・医薬品中間体の世界市場規模：用途別 ・医薬品中間体の世界市場規模：エンドユーザー別 ・医薬品中間体の世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Pharmaceutical Intermediates Market – Scope of Report
TMR’s report on the global pharmaceutical intermediates market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market over the forecast period from 2021 to 2031. The report provides the overall revenue of the global pharmaceutical intermediates market for the period of 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR) of the global pharmaceutical intermediates market for the forecast period of 2021–2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global pharmaceutical intermediates market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomena in the global pharmaceutical intermediates market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments in the scope of the study. Moreover, the report sheds light on changing competitive dynamics in the pharmaceutical intermediates market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the pharmaceutical intermediates market.
The report also delves into the competitive landscape of the global pharmaceutical intermediates market. Key players operating in the global pharmaceutical intermediates market have been identified and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the pharmaceutical intermediates market profiled in this report.
Key Questions Answered in Pharmaceutical Intermediates Market Report
How does the development of pharmaceutical intermediates provide scope of growth in the global pharmaceutical intermediates market?
How alliances and partnerships between players are widening the scope of new line of therapies for pharmaceutical intermediates?
What are the revenue share projections of key segments under various criteria in the pharmaceutical intermediates market during the forecast period?
Which segment is likely to register highest revenue until the end of the forecast period in 2031?
How is the evolving health care system in developing countries in Asia Pacific making an impact on the overall pharmaceutical intermediates market?
Pharmaceutical Intermediates Market – Research Objectives and Research Approach
The comprehensive report on the global pharmaceutical intermediates market begins with an overview of the market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study and healthcare compliances laid down by accredited agencies in the purview of line of procedure for pharmaceutical intermediates.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into smaller ones. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global pharmaceutical intermediates market in terms of product, application, end user, and region. Key segments under each criteria are studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global pharmaceutical intermediates market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pharmaceutical Intermediates Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Pharmaceutical Intermediates Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
5.2. Key Industry Events (mergers and acquisitions, new product development, etc.)
5.3. Pharmaceutical Intermediates Products/Brands List
6. Global Pharmaceutical Intermediates Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.1.1. Key Findings / Developments
6.2. Global Pharmaceutical Intermediates Market Value Forecast, by Product, 2017–2031
6.2.1. Bulk Drug Intermediate
6.2.1.1. Chiral Intermediate
6.2.1.2. Achiral Intermediate
6.2.2. Custom Intermediate
6.3. Global Pharmaceutical Intermediates Market Attractiveness Analysis, by Product
7. Global Pharmaceutical Intermediates Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.1.1. Key Findings / Developments
7.2. Global Pharmaceutical Intermediates Market Value Forecast, by Application, 2017–2031
7.2.1. Cardiology
7.2.2. Oncology
7.2.3. Endocrinology
7.2.4. Infectious Diseases
7.2.5. Orthopedics
7.2.6. Neurology
7.2.7. Gastroenterology
7.2.8. Dermatology
7.2.9. Inflammatory & Pain Management
7.2.10. Ophthalmology
7.2.11. Others
7.3. Global Pharmaceutical Intermediates Market Attractiveness Analysis, by Application
8. Global Pharmaceutical Intermediates Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.1.1. Key Findings / Developments
8.2. Global Pharmaceutical Intermediates Market Value Forecast, by End-user, 2017–2031
8.2.1. Pharmaceutical & Biotechnology Companies
8.2.2. CROs & CMOs
8.3. Global Pharmaceutical Intermediates Market Attractiveness Analysis, by End-user
9. Global Pharmaceutical Intermediates Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Pharmaceutical Intermediates Market Value Forecast by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Pharmaceutical Intermediates Market Attractiveness Analysis, by Country/Region
10. North America Pharmaceutical Intermediates Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Pharmaceutical Intermediates Market Value Forecast, by Product, 2017–2031
10.2.1. Bulk Drug Intermediate
10.2.1.1. Chiral Intermediate
10.2.1.2. Achiral Intermediate
10.2.2. Custom Intermediate
10.3. North America Pharmaceutical Intermediates Market Value Forecast, by Application, 2017–2031
10.3.1. Cardiology
10.3.2. Oncology
10.3.3. Endocrinology
10.3.4. Infectious Diseases
10.3.5. Orthopedics
10.3.6. Neurology
10.3.7. Gastroenterology
10.3.8. Dermatology
10.3.9. Inflammatory & Pain Management
10.3.10. Ophthalmology
10.3.11. Others
10.4. North America Pharmaceutical Intermediates Market Value Forecast, by End-user, 2017–2031
10.4.1. Pharmaceutical & Biotechnology Companies
10.4.2. CROs & CMOs
10.5. North America Pharmaceutical Intermediates Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. North America Pharmaceutical Intermediates Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Pharmaceutical Intermediates Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Pharmaceutical Intermediates Market Value Forecast, by Product, 2017–2031
11.2.1. Bulk Drug Intermediate
11.2.1.1. Chiral Intermediate
11.2.1.2. Achiral Intermediate
11.2.2. Custom Intermediate
11.3. Europe Pharmaceutical Intermediates Market Value Forecast, by Application, 2017–2031
11.3.1. Cardiology
11.3.2. Oncology
11.3.3. Endocrinology
11.3.4. Infectious Diseases
11.3.5. Orthopedics
11.3.6. Neurology
11.3.7. Gastroenterology
11.3.8. Dermatology
11.3.9. Inflammatory & Pain Management
11.3.10. Ophthalmology
11.3.11. Others
11.4. Europe Pharmaceutical Intermediates Market Value Forecast, by End-user, 2017–2031
11.4.1. Pharmaceutical & Biotechnology Companies
11.4.2. CROs & CMOs
11.5. Europe Pharmaceutical Intermediates Market Value Forecast by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Pharmaceutical Intermediates Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Pharmaceutical Intermediates Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Pharmaceutical Intermediates Market Value Forecast, by Product, 2017–2031
12.2.1. Bulk Drug Intermediate
12.2.1.1. Chiral Intermediate
12.2.1.2. Achiral Intermediate
12.2.2. Custom Intermediate
12.3. Asia Pacific Pharmaceutical Intermediates Market Value Forecast, by Application, 2017–2031
12.3.1. Cardiology
12.3.2. Oncology
12.3.3. Endocrinology
12.3.4. Infectious Diseases
12.3.5. Orthopedics
12.3.6. Neurology
12.3.7. Gastroenterology
12.3.8. Dermatology
12.3.9. Inflammatory & Pain Management
12.3.10. Ophthalmology
12.3.11. Others
12.4. Asia Pacific Pharmaceutical Intermediates Market Value Forecast, by End-user, 2017–2031
12.4.1. Pharmaceutical & Biotechnology Companies
12.4.2. CROs & CMOs
12.5. Asia Pacific Pharmaceutical Intermediates Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Pharmaceutical Intermediates Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Pharmaceutical Intermediates Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Pharmaceutical Intermediates Market Value Forecast, by Product, 2017–2031
13.2.1. Bulk Drug Intermediate
13.2.1.1. Chiral Intermediate
13.2.1.2. Achiral Intermediate
13.2.2. Custom Intermediate
13.3. Latin America Pharmaceutical Intermediates Market Value Forecast, by Application, 2017–2031
13.3.1. Cardiology
13.3.2. Oncology
13.3.3. Endocrinology
13.3.4. Infectious Diseases
13.3.5. Orthopedics
13.3.6. Neurology
13.3.7. Gastroenterology
13.3.8. Dermatology
13.3.9. Inflammatory & Pain Management
13.3.10. Ophthalmology
13.3.11. Others
13.4. Latin America Pharmaceutical Intermediates Market Value Forecast, by End-user, 2017–2031
13.4.1. Pharmaceutical & Biotechnology Companies
13.4.2. CROs & CMOs
13.5. Latin America Pharmaceutical Intermediates Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Pharmaceutical Intermediates Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Pharmaceutical Intermediates Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Pharmaceutical Intermediates Market Value Forecast, by Product, 2017–2031
14.2.1. Bulk Drug Intermediate
14.2.1.1. Chiral Intermediate
14.2.1.2. Achiral Intermediate
14.2.2. Custom Intermediate
14.3. Middle East & Africa Pharmaceutical Intermediates Market Value Forecast, by Application, 2017–2031
14.3.1. Cardiology
14.3.2. Oncology
14.3.3. Endocrinology
14.3.4. Infectious Diseases
14.3.5. Orthopedics
14.3.6. Neurology
14.3.7. Gastroenterology
14.3.8. Dermatology
14.3.9. Inflammatory & Pain Management
14.3.10. Ophthalmology
14.3.11. Others
14.4. Middle East & Africa Pharmaceutical Intermediates Market Value Forecast, by End-user, 2017–2031
14.4.1. Pharmaceutical & Biotechnology Companies
14.4.2. CROs & CMOs
14.5. Middle East & Africa Pharmaceutical Intermediates Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Pharmaceutical Intermediates Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis/Ranking, by Company, 2020
15.3. Company Profiles
15.3.1. BASF SE
15.3.1.1. Company Description
15.3.1.2. Business Overview
15.3.1.3. Strategic Overview
15.3.1.4. SWOT Analysis
15.3.2. Lonza Group
15.3.2.1. Company Description
15.3.2.2. Business Overview
15.3.2.3. Strategic Overview
15.3.2.4. SWOT Analysis
15.3.3. Evonik Industries AG
15.3.3.1. Company Description
15.3.3.2. Business Overview
15.3.3.3. Strategic Overview
15.3.3.4. SWOT Analysis
15.3.4. Cambrex Corporation
15.3.4.1. Company Description
15.3.4.2. Business Overview
15.3.4.3. Strategic Overview
15.3.4.4. SWOT Analysis
15.3.5. DSM
15.3.5.1. Company Description
15.3.5.2. Business Overview
15.3.5.3. Strategic Overview
15.3.5.4. SWOT Analysis
15.3.6. Aceto
15.3.6.1. Company Description
15.3.6.2. Business Overview
15.3.6.3. Strategic Overview
15.3.6.4. SWOT Analysis
15.3.7. Albemarle Corporation
15.3.7.1. Company Description
15.3.7.2. Business Overview
15.3.7.3. Strategic Overview
15.3.7.4. SWOT Analysis
15.3.8. Vertellus
15.3.8.1. Company Description
15.3.8.2. Business Overview
15.3.8.3. Strategic Overview
15.3.8.4. SWOT Analysis
15.3.9. Chemcon Speciality Chemicals Ltd.
15.3.9.1. Company Description
15.3.9.2. Business Overview
15.3.9.3. Strategic Overview
15.3.9.4. SWOT Analysis
15.3.10. chiracon GmbH
15.3.10.1. Company Description
15.3.10.2. Business Overview
15.3.10.3. Strategic Overview
15.3.10.4. SWOT Analysis
15.3.11. A. R. Life Sciences Private Limited
15.3.11.1. Company Description
15.3.11.2. Business Overview
15.3.11.3. Strategic Overview
15.3.11.4. SWOT Analysis
Table 01: Global Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 02: Global Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Bulk Drug Intermediate, 2017–2031
Table 03: Global Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 04: Global Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 05: Global Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 06: Global Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 08: North America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 09: North America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Bulk Drug Intermediate, 2017–2031
Table 10: North America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 11: North America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 12: North America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Europe Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Europe Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 15: Europe Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Bulk Drug Intermediate, 2017–2031
Table 16: Europe Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 17: Europe Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 18: Europe Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 19: Asia Pacific Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 20: Asia Pacific Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 21: Asia Pacific Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Bulk Drug Intermediate, 2017–2031
Table 22: Asia Pacific Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 23: Asia Pacific Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Asia Pacific Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 25: Latin America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 26: Latin America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 27: Latin America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Bulk Drug Intermediate, 2017–2031
Table 28: Latin America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 29: Latin America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 30: Latin America Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 31: Middle East & Africa Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 32: Middle East & Africa Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 33: Middle East & Africa Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Bulk Drug Intermediate, 2017–2031
Table 34: Middle East & Africa Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 35: Middle East & Africa Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 36: Middle East & Africa Pharmaceutical Intermediates Market Value (US$ Mn) Forecast, by End-user, 2017–2031